ArticleMaterials today. Bio2025
Redirecting the route: Monocyte-mediated delivery of oHSV-1 across a human BBB-on-chip model.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Antitumor activity of Oncolytic Herpes Symplex Virus Type 1 and photodynamic therapy in in vitro preclinical models of glioblastoma.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic viruses (OVs) that selectively replicate within cancer cells represent a promising therapeutic strategy for refractory or difficult-to-treat tumors such as Glioblastoma (GBM). In this study, we develop and validate a human microfluidic blood brain barrier (BBB) model to evaluate the potential of cell-based OVs delivery targeting the central nervous system. We demonstrate that circulating leukocytes (monocytes), serve as effective carrier cells for the delivery of a neuroattenuated strain of oncolytic herpes simplex virus type 1 (oHSV-1) to GBM. Human monocytes infected with oHSV-1 and perfused through the device successfully traverse the BBB and migrate toward human GBM spheroids, where they deliver the virus and initiate infection. Notably, monocyte-mediated oHSV-1 delivery to the tumor occurs with
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.